注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Arrowhead Pharmaceuticals Inc通过沉默导致顽固性疾病的基因来开发治疗药物。该公司使用核糖核酸(RNA)化学和递送模式的组合,该公司的疗法触发RNA干扰机制,以诱导目标基因的快速、深度和持久的敲低。该公司专注于开发具有遗传基础的疾病的药物,其特征是一种或多种蛋白质的过度生产。该公司的管线产品包括用于高甘油三酯血症的ARO-APOC3、用于血脂异常的ARO-ANG3、用于囊性纤维化的ARO-ENaC2、用于面肩肱型肌营养不良症的ARO-DUX4、用于导致COVID-19的冠状病毒和其他可能的未来肺传播病原体的ARO-COV、用于补体介导疾病的ARO-C3、用于各种粘液阻塞或炎症性肺部疾病的ARO-RAGE和ARO-MUC5AC,以及用于特发性肺纤维化的ARO-MMP7。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Douglass B. Given | 69 | 2010 | Chairman of the Board |
Christopher R. Anzalone | 52 | 2007 | CEO, President & Director |
Robert G. Gish | - | - | Chairman of Hepatitis B Clinical Advisory Board |
William D. Waddill | 65 | 2018 | Independent Director |
Michael S. Perry | 64 | 2011 | Independent Lead Director |
Mauro Ferrari | 64 | 2008 | Independent Director |
Carlo Ferrari | - | - | Member of Hepatitis B Clinical Advisory Board |
Stephen Alister Locarnini | - | - | Member of Hepatitis B Clinical Advisory Board |
Ching-Lung Lai | - | - | Member of Hepatitis B Clinical Advisory Board |
Jeffrey H. Teckman | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Johnson Y. N. Lau | - | - | Member of Hepatitis B Clinical Advisory Board |
James K. Stoller | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Rohit Loomba | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Victoria M. Vakiener | 59 | 2022 | Independent Director |
Adeoye Y. Olukotun | 78 | 2020 | Independent Director |
Mark M. Davis | - | - | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
Hongbo Lu | 52 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核